Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · Real-Time Price · USD
8.20
+0.04 (0.49%)
Sep 18, 2026, 4:00 PM EDT - Market closed
Xeris Biopharma Holdings Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 335.41 | 291.85 | 203.07 | 163.91 | 110.25 | 49.59 | |
Revenue Growth | 36.33% | 43.72% | 23.89% | 48.68% | 122.32% | 142.67% |
Cost of Revenue | 45.03 | 42.57 | 36.83 | 28.65 | 22.63 | 13.32 |
Gross Profit | 290.39 | 249.28 | 166.24 | 135.27 | 87.61 | 36.27 |
Selling, General & Admin | 208.14 | 182.37 | 163.48 | 146.1 | 137.75 | 116.06 |
Research & Development | 34.81 | 31.17 | 25.56 | 22.34 | 20.97 | 25.16 |
Amortization of Goodwill & Intangibles | 10.84 | 10.84 | 10.84 | 10.84 | 10.84 | 0.55 |
Operating Expenses | 253.79 | 224.38 | 199.88 | 179.28 | 169.55 | 141.77 |
Operating Income | 36.59 | 24.9 | -33.65 | -44.01 | -81.94 | -105.5 |
Interest Expense | -28.25 | -29.08 | -30.49 | -26.61 | -14.1 | -7.18 |
Interest & Investment Income | 5.28 | 4.74 | 5.32 | 4.75 | 2.58 | 0.73 |
Other Non Operating Income (Expenses) | - | - | 0.01 | 0 | 1.76 | -0.7 |
EBT Excluding Unusual Items | 13.62 | 0.55 | -58.8 | -65.87 | -91.7 | -112.66 |
Merger & Restructuring Charges | - | - | - | - | - | -9.66 |
Gain (Loss) on Sale of Investments | - | - | - | - | - | -0.41 |
Other Unusual Items | -30.78 | - | 1.7 | 2.36 | -4.38 | - |
Pretax Income | -17.17 | 0.55 | -57.1 | -63.5 | -96.08 | -122.73 |
Income Tax Expense | - | - | -2.27 | -1.25 | -1.42 | - |
Net Income | -17.17 | 0.55 | -54.84 | -62.26 | -94.66 | -122.73 |
Net Income to Common | -17.17 | 0.55 | -54.84 | -62.26 | -94.66 | -122.73 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 168 | 160 | 147 | 138 | 136 | 79 |
Shares Outstanding (Diluted) | 168 | 173 | 147 | 138 | 136 | 79 |
Shares Change | 10.29% | 17.69% | 6.61% | 1.51% | 71.62% | 85.32% |
EPS (Basic) | -0.10 | 0.00 | -0.37 | -0.45 | -0.70 | -1.55 |
EPS (Diluted) | -0.10 | 0.00 | -0.37 | -0.45 | -0.70 | -1.55 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 55.67 | 27.93 | -37.85 | -49.29 | -103.42 | -96.62 |
Free Cash Flow Per Share | 0.33 | 0.16 | -0.26 | -0.36 | -0.76 | -1.22 |
Gross Margin | 86.58% | 85.41% | 81.86% | 82.52% | 79.47% | 73.14% |
Operating Margin | 10.91% | 8.53% | -16.57% | -26.85% | -74.32% | -212.74% |
Profit Margin | -5.12% | 0.19% | -27.00% | -37.98% | -85.86% | -247.48% |
Free Cash Flow Margin | 16.60% | 9.57% | -18.64% | -30.07% | -93.80% | -194.84% |
EBITDA | 48.77 | 37.05 | -21.58 | -31.68 | -69.7 | -103.62 |
EBITDA Margin | 14.54% | 12.70% | -10.63% | -19.33% | -63.22% | -208.95% |
D&A For EBITDA | 12.18 | 12.16 | 12.07 | 12.33 | 12.24 | 1.88 |
EBIT | 36.59 | 24.9 | -33.65 | -44.01 | -81.94 | -105.5 |
EBIT Margin | 10.91% | 8.53% | -16.57% | -26.85% | -74.32% | -212.74% |
Revenue as Reported | 335.41 | 291.85 | 203.07 | 163.91 | 110.25 | 49.59 |